Significant Ownership of SAMLYN CAPITAL, LLC
- Signature - Title
- By: Samlyn, LP, its sole member, By: Samlyn GP, LLC, its general partner, /s/ Robert Pohly* - Robert Pohly / Managing Member
- Location
- New York, NY
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by SAMLYN CAPITAL, LLC.
Follow Filing Activity
Follow SAMLYN CAPITAL, LLC and return when a new Schedule 13D/G filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Continue schedule research
Related filing hubs for this reporting manager, useful for reinforcing crawl paths across the schedule cluster.
Significant Ownership of SAMLYN CAPITAL, LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| PCT | PureCycle Technologies, Inc. | Common Stock, par value $0.001 per share | 7.2% | $179,440,876 | -$40,162,309 | 13,645,694 | -18% | Samlyn Capital, LLC | 30 Sep 2025 |
| VINP | Vinci Partners Investments Ltd. | Class A Common Shares, par value US$0.00005 per share | 4.8% | $22,695,339 | -$34,013 | 2,356,733 | -0.15% | SAMLYN CAPITAL, LLC | 31 Mar 2025 |
| NKTR | Nektar Therapeutics | Common Stock, $0.0001 par value | 0% | $0 | -$7,153,616 | 0 | -100% | SAMLYN CAPITAL, LLC | 31 Mar 2025 |
| CRVS | Corvus Pharmaceuticals, Inc. | Common Stock, par value $0.0001 per share | 0% | $0 | -$15,857,146 | 0 | -100% | SAMLYN CAPITAL, LLC | 30 Jun 2025 |
| INZY | Inozyme Pharma, Inc. | Common Stock, par value $0.0001 per share | 0% | $0 | 0 | Samlyn Capital, LLC | 31 Dec 2024 |
Schedules 13D/G Reported by SAMLYN CAPITAL, LLC:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.